Article

Metastatic renal cell carcinoma to hemangioblastoma in von Hippel-Lindau disease

Department of Pathology and Laboratory Medicine, Weill Medical College of Cornell University, New York, NY, USA.
Archives of pathology & laboratory medicine (Impact Factor: 2.88). 04/2007; 131(4):641-5. DOI: 10.1043/1543-2165(2007)131[641:MRCCTH]2.0.CO;2
Source: PubMed

ABSTRACT A case of metastatic renal cell carcinoma (RCC) to a capillary hemangioblastoma (HAB) of the central nervous system in a 52-year-old woman with von Hippel-Lindau (vHL) syndrome is described. We review the literature on metastatic RCC to HAB, summarize the histologic and immunohistochemical features that can distinguish between the 2 tumors, and comment on the significance of such a finding in terms of the clinical diagnosis of vHL. We found the expression of CAM 5.2, RCC antigen, and CD10 to be strong in RCC and absent in HAB and, conversely, staining with Leu-7, neural cell adhesion molecule, and inhibin-alpha was present in HAB but weak or absent in RCC. These antibodies can be used to differentiate these entities, provided one is astute in recognizing the possibility of their coexistence.

0 Followers
 · 
64 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: von Hippel-Lindau (VHL) disease is an inherited multisystem familial cancer syndrome caused by mutations of the VHL gene on chromosome 3p25. A wide variety of neoplastic processes are known to be associated with VHL disease. The consequences of the VHL mutations and the pathway for tumor development continue to be elucidated. This paper will detail the variety of tumors associated with VHL disease and discuss the genetic mechanisms that lead to the predisposition for neoplasia.
    Advances in anatomic pathology 06/2008; 15(3):165-71. DOI:10.1097/PAP.0b013e31816f852e · 3.10 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The distinction between central nervous system (CNS) metastases of clear cell renal cell carcinoma (RCC) and CNS haemangioblastoma still poses a challenge to the pathologist. Since both entities occur in von Hippel-Lindau disease, this aggravates the issue. The antibody renal cell carcinoma marker (RCC-ma) has been suggested to identify primary RCCs specifically, but its value for diagnosing metastases of RCC is controversial. The aim was to assess two distinct clones of the RCC-ma for their potential to: (i) identify primary RCCs and (ii) differentiate between CNS metastases of clear cell RCC and CNS haemangioblastomas. Using tissue microarrays, 77% (n = 363; PN-15) and 66% (n = 355; 66.4C2) of clear cell RCCs, and 93% (PN-15) and 74% (66.4C2) of papillary RCCs (n = 46) were immunopositive for RCC-ma, whereas none of the investigated chromophobe RCCs (n = 22) or any of the oncocytomas (n = 15) showed immunoreactivity. Importantly, 50.9% of CNS metastases of clear cell RCCs (n = 55) exhibited RCC-ma expression, whereas all CNS haemangioblastomas (71) were negative. Both RCC-ma clones, despite some variation in their sensitivity to detect clear cell and papillary RCCs, are of value in differentiating subtypes of primary RCC and are excellent markers for discriminating clear cell lesions in the brain.
    Histopathology 06/2008; 52(6):674-81. DOI:10.1111/j.1365-2559.2008.03003.x · 3.30 Impact Factor
  • Source
    Clinical Orthopaedics and Related Research 08/2008; 466(7):1764-8. DOI:10.1007/s11999-008-0139-1 · 2.88 Impact Factor
Show more